Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid
Interleukin-6 (IL-6) is a multifunctional cytokine which contributes to inXammation and tissue injury in
several diseases. Thus, inhibition of IL-6 production may
be a useful strategy for treatment of patients with diseases
such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). A synthetic nonpsychoactive cannabinoid,
ajulemic acid (AjA), prevents joint damage in experimental
arthritis. Results of experiments presented here indicate that
addition of AjA (3–30 M) to human monocyte derived
macrophages in vitro reduces steady state levels of IL-6
mRNA and the subsequent secretion of IL-6 from LPS
stimulated cells. Although AjA binds to and activates
PPAR, its anti IL-6 eVects are PPAR independent. These
studies provide evidence to support the view that AjA may
prove to be an eVective, safe antiinXammatory agent.
This library aims to empower you with knowledge but it does not replace the personalized advice and guidance a healthcare professional can provide. Before implementing any changes to your health regimen based on the contents of this library, we strongly advise you to consult with a qualified healthcare professional. Your doctor’s expertise is essential for interpreting how these insights may apply to your unique health circumstances.